KID Syndrome
Keratitis-Ichthyosis-Deafness syndrome. Caused by GJB2 (Connexin 26) mutations. Multisystem condition requiring specialist care across several disciplines.
KID Syndrome is now also classified as GJB2-sEDD under the new gene-based EDD system (syndromic, as it affects skin, eyes, and hearing). Both names remain valid.
Vascularising keratitis — blood vessels grow into the cornea. Progressive, can impair vision. Ophthalmology is critical. Not caused by infection.
Leathery, keratotic skin — especially face, scalp, and extremities. Verrucous (wart-like) plaques common. Can be very disfiguring.
Sensorineural hearing loss — typically profound and present from birth. Hearing aids or cochlear implants often required.
Significantly increased risk of squamous cell carcinoma (SCC) — especially of the skin, mouth, and oesophagus. Lifelong surveillance is essential.
Daily Skincare Routine
- Bath or shower (20 min) — Warm, not hot. KID keratosis benefits from soaking and scale softening.
- Scale removal on wet skin — Gentle scrub sponge on keratotic areas. Scalp may need medicated shampoo (Capasal, salicylic acid).
- Keratolytic cream — Urea 20–40%, salicylic acid 2–6%, or lactic acid to keratotic areas
- Emollient — Epaderm ointment or Diprobase over the full body
- Eye lubricant drops — Essential every morning. Follow ophthalmologist regime precisely.
- Hearing aid check — Ensure hearing aids are clean, functioning and charged
- Sun protection SPF50+ — Critical for skin cancer prevention. Broad-spectrum, daily, all year.
- Therapeutic bath (25–30 min) with bath oil
- High-strength keratolytic on face, scalp, hands, and feet where keratosis is worst
- Full body emollient application
- Oral care — Check mouth for any new lesions or sores. Report any that persist beyond 2 weeks immediately.
- Eye ointment — Overnight protection for keratitis. Follow ophthalmologist protocol.
- Scalp treatment if needed — Salicylic acid or coconut oil overnight for scalp keratosis
- Lubricant eye drops (e.g., Viscotears, Systane) every 2–4 hours during the day
- Topical ciclosporin eye drops if prescribed for vascularising keratitis (Ikervis) — follow ophthalmologist dose
- UV-blocking wraparound sunglasses outdoors — reduces keratitis progression
- Overnight eye ointment (Lacrilube or Simple Eye Ointment)
- Annual ophthalmology review minimum — more frequent if keratitis is active
- Corneal transplant may be considered in severe cases
- Hearing aids: fitted early — ideally within first months of life. Regular audiologist follow-up.
- Cochlear implant: may be considered for profound sensorineural hearing loss — discuss with ENT/audiology
- Ear canal care: KID skin can produce scale in ear canals. Regular GP microsuction. Olive oil ear drops to soften.
- Hearing loops, subtitles, and other assistive technology — claim as reasonable adjustment under Equality Act
- National Deaf Children's Society or Action on Hearing Loss for additional support
Medications
| Drug | Target | Efficacy | Key Points |
|---|---|---|---|
| Acitretin (Neotigason) | Skin hyperkeratosis | 75% | First-line systemic for skin component. Requires monitoring. |
| Urea/salicylic acid keratolytics | Skin scaling | 65% | Essential topical. High strength needed on keratotic areas. |
| Ciclosporin eye drops (Ikervis) | Vascularising keratitis | 70% | Specialist ophthalmologist prescription. Reduces corneal inflammation. |
| Emollients (Epaderm, Diprobase) | Skin barrier | 60% | Cornerstone of daily management |
| Regular dermatological surveillance | SCC prevention/detection | Essential | Annual skin check — can be life-saving |
Cancer Surveillance Protocol
Annual checks (minimum):
- Full skin examination by experienced dermatologist — check all sites especially scalp, face, hands
- Oral mucosal examination — check inside cheeks, tongue, gum margins
- Self-examination monthly — check for new persistent sores, thickenings, or non-healing areas
- Report immediately: Any skin lesion that doesn't heal within 4 weeks, bleeds easily, or grows rapidly
- Oesophageal symptoms: Difficulty swallowing, pain on swallowing — these need prompt investigation (endoscopy)
Key Research — Emerging Treatments
2021 — Scientific Reports (Nature)
Connexin hemichannel inhibition reduces epidermal pathology in KID syndrome model
Topically applied flufenamic acid (FFA) — a connexin hemichannel blocker — substantially reduced epidermal pathology in vivo in the Cx26-G45E mouse model. The most mechanistically targeted therapeutic advance for KID syndrome to date. The KID syndrome mutation causes connexin 26 hemichannels to stay open when they should close — FFA blocks this. Human trials not yet initiated.
2026 — Pediatric Dermatology (Harvard / Boston Children's Hospital)
Adalimumab for refractory dissecting cellulitis of the scalp in a paediatric KID syndrome patient
A teenage boy with KID syndrome and severe dissecting cellulitis of the scalp (DCS) — a chronic inflammatory condition causing painful draining nodules and scarring alopecia — failed to respond to antibiotics, surgery, and steroid injections. Treatment with adalimumab (TNF-α inhibitor) led to marked reduction in drainage and pain with visible hair regrowth. First published paediatric case of adalimumab for DCS complicating KID syndrome. Case report only, but provides a treatment option for a previously refractory KID complication.
SCC Risk — Updated Figures
Squamous cell carcinoma: 12–15% lifetime risk, highest in Cx26-D50N carriers
Multiple PubMed case series confirm SCC develops in 12–15% of KID syndrome patients. Mucosal sites (mouth, oesophagus) are particularly at risk. The Cx26-D50N mutation is associated with higher malignancy risk. Lifelong annual dermatological surveillance, monthly self-examination, and prompt investigation of non-healing lesions are essential.
Red Flags
- Any skin lesion that doesn't heal in 4 weeks, bleeds, or grows rapidly — could be SCC
- Sudden vision change, eye pain, or marked worsening of keratitis
- Difficulty swallowing or painful swallowing (oesophageal involvement)
- Widespread skin infection with fever